Abstract: A small molecule TNF-? inhibitor is disclosed. The compound has an activity of inhibiting the formation of a TNF-? homotrimer by specifically binding to the binding cavity of a TNF-? homodimer. A composition containing the compound as well as uses of the compound and the composition in preventing or treating autoimmune diseases and/or inflammatory diseases are disclosed. Extracellular inactivation of TNF-? through protein-protein interface destruction is the most innovative and effective method for alleviating chronic systemic inflammatory states, and TIM series compounds, which have better efficacy and lower toxicity than those of existing TNF inhibitors and have oral bioavailability, can be effectively used as leading anti-inflammatory molecules.